BridgeMD
BOOSTCAMP: Boosting the endocannabinoid system before the treatment of anxiety symptoms
EU CTIS ID: 2024-514783-78-00
What this study is testing
to examine the effects of a 2-week administration of Cannabidiol (CBD) in alleviating anxiety symptoms before anxiety or PTSD treatments in Dutch uniformed personnel
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Dutch uniformed personnel, which are (former) police-officers, firefighters, ambulance paramedics, military personnel or veterans.
- Age between 18-65
- Waiting for therapy for the treatment of a trauma and stressor-related and/or an anxiety disorder (as determined by the MINI PLUS psychiatric interview)
You likely can't join if
- Severe co-morbidity (severe major depressive or bipolar disorder and/or psychosis)
- Alcohol and/or drug dependence
- Inability to adequately read or speak Dutch
- (a history of) epilepsy or brain damage, cardiac, renal or liver abnormalities
- (a history of) allergies to medication (adverse reactions or rash)
- Individuals taking certain medications known to have potential interactions with CBD (i.e., steroids, HMG-CoA reductase inhibitors, calcium channel blockers, antihistamines, antivirals, immune modulators, benzodiazepines, anti-arrhythmic, antibiotics, anesthetics, antipsychotics, antidepressants, anti-epileptics, beta blockers, proton pump inhibitors, NSAIDs, angiotensin II blockers, oral hypoglycemic agents, and sulfonylureas)
See the full eligibility criteria
- Dutch uniformed personnel, which are (former) police-officers, firefighters, ambulance paramedics, military personnel or veterans.
- Age between 18-65
- Waiting for therapy for the treatment of a trauma and stressor-related and/or an anxiety disorder (as determined by the MINI PLUS psychiatric interview)
- Severe co-morbidity (severe major depressive or bipolar disorder and/or psychosis)
- Alcohol and/or drug dependence
- Inability to adequately read or speak Dutch
- (a history of) epilepsy or brain damage, cardiac, renal or liver abnormalities
- (a history of) allergies to medication (adverse reactions or rash)
- Individuals taking certain medications known to have potential interactions with CBD (i.e., steroids, HMG-CoA reductase inhibitors, calcium channel blockers, antihistamines, antivirals, immune modulators, benzodiazepines, anti-arrhythmic, antibiotics, anesthetics, antipsychotics, antidepressants, anti-epileptics, beta blockers, proton pump inhibitors, NSAIDs, angiotensin II blockers, oral hypoglycemic agents, and sulfonylureas)
- Used cannabis, synthetic cannabinoid, cannabinoid analogue, or any CBD or THC-containing product within 30 days of eligibility screening.
- Individuals that had been diagnosed with intestinal, liver, or renal diseases that would affect absorption or clearance of CBD
- For women: pregnant, a wish to become pregnant, or nursing
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.